TDSGF (Telo Genomics) Moat Score: 2/10 (As of Jul. 01, 2026)


What is Telo Genomics Moat Score?

Telo Genomics TDSGF -27.59% Moat Score is 2 as of Jul. 01, 2026. The stock has 2 warning signs investors should review. Among 216 Medical Diagnostics & Research companies, Telo Genomics ranks better than 69.44% on this metric.

Telo Genomics has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Telo Genomics has No Moat: Telo Genomics Corp lacks significant market leadership and customer switching costs. The company does not have strong brand strength or durable cost advantages. Its intellectual property and innovation capabilities are not sufficient to establish a competitive edge.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Telo Genomics might have No Moat - Very weak/transient advantages.

Telo Genomics  (OTCPK:TDSGF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Telo Genomics Moat Score Related Terms

TDSGF vs TMO, DHR, IDXX: Moat Score Comparison

For the Diagnostics & Research subindustry, Telo Genomics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Telo Genomics Moat Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Telo Genomics's Moat Score distribution charts can be found below:

* The bar in red indicates where Telo Genomics's Moat Score falls into.


Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Telo Genomics (TDSGF) has a Moat Score of 2 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Telo Genomics ranks #66 out of 216 companies in the Medical Diagnostics & Research industry, placing it in the top 30.6%.
Is Telo Genomics' Moat Score too high?
Telo Genomics' current Moat Score is 2. Based on the distribution chart, Telo Genomics ranks #66 out of 216 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint.
How does Telo Genomics' Moat Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Telo Genomics ranks #66 out of 216 companies for Moat Score. This puts Telo Genomics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Diagnostics & Research company?
A good Moat Score depends on the Medical Diagnostics & Research industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Telo Genomics's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telo Genomics stock overvalued right now?
Telo Genomics (TDSGF) has a current Moat Score of 2. The current Moat Score is 2. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Telo Genomics (TDSGF), the current Moat Score is 2 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Telo Genomics Business Description

Other Exchanges 3D0A:GermanyTELO:Canada
Address 2255 York Avenue, Suite 203, Vancouver, BC, CAN, V6K 1C5
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in developing diagnostic and prognostic products that may save lives, improve the quality of life, and reduce the cost of care associated with numerous diseases that display genomic instability. The company has a single operating segment, focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions.